One of the most-asked questions about tirzepatide in 2026 is "can I still buy compounded tirzepatide?" The short answer for therapeutic use is largely no: the FDA officially resolved the tirzepatide shortage in 2024 to 2025, which under FDA Section 503A and 503B compounding rules generally restricts pharmacies from preparing tirzepatide for human use. The longer answer is that this regulatory status applies only to the compounded therapeutic channel. The Research Use Only research peptide channel for tirzepatide (sold as GLP-2 TZ) operates under entirely separate regulations and is unaffected by the compounding restrictions.
Can I Still Buy Compounded Tirzepatide? (2026 Research Context)
GLP-2 TZ · Published May 5, 2026 · Updated May 18, 2026 · 9 min read
Quick Answer
Compounded tirzepatide for human use was largely restricted by the FDA after the official shortage was resolved in 2024 to 2025. Most compounding pharmacies can no longer prepare tirzepatide for therapeutic use as of 2026. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under separate regulations and is unaffected by the compounding restrictions; research labs continue to source GLP-2 TZ for laboratory and in-vitro work. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
- The FDA Compounding Framework Explained
- The Tirzepatide Shortage and Its Resolution
- Research Use Only Tirzepatide Operates in a Separate Channel
- What Research Labs Source for Tirzepatide Research
- How Research Peptide Tirzepatide Differs From Compounded Therapeutic Tirzepatide
- What Comes With RUO Tirzepatide From Reliable Suppliers
- External References for Compounding and Regulatory Context
- Bottom Line
- Related Research Reading
- Frequently Asked Questions
- Glossary
Frequently Asked Questions
Is compounded tirzepatide still available?
+
Largely no, as of 2026. The FDA officially declared the tirzepatide shortage resolved in 2024 to 2025, which under FDA Section 503A and 503B rules generally restricts compounding pharmacies from preparing tirzepatide for human therapeutic use. Some narrow exceptions for individual patient prescriptions may apply, but the broad compounding access during the shortage period has ended.
Why did compounded tirzepatide become unavailable?
+
FDA compounding rules allow pharmacies to compound a drug only when it is on the official FDA shortage list. When the shortage ends, the regulatory permission to compound the drug for human therapeutic use also ends. Tirzepatide was on the shortage list during 2023 to 2024 due to demand exceeding supply, and the resolution of that shortage triggered the standard restoration of compounding restrictions.
Does this affect research peptide tirzepatide (GLP-2 TZ)?
+
No. Research-grade tirzepatide sold as GLP-2 TZ under Research Use Only labeling operates in a completely separate regulatory channel from compounded tirzepatide. RUO research peptides are not drugs, are not dispensed by pharmacies, and are not subject to the compounding pharmacy regulations. Research labs continue to source GLP-2 TZ for laboratory and in-vitro work.
Glossary
Key terms used in this article.
- FDA Section 503A
- The provision of the Federal Food, Drug, and Cosmetic Act governing traditional compounding pharmacies that prepare medications for individual patients under physician prescription.
- FDA Section 503B
- The provision of the FFDCA governing outsourcing facilities that prepare compounded medications for office use without patient-specific prescriptions, registered with and inspected by the FDA.
- FDA Drug Shortage List
- The official list maintained by the FDA of drugs in current shortage. Listing on this list affects compounding regulations, importation rules, and supply chain considerations.
- Compounding Pharmacy
- A state-licensed pharmacy that prepares customized medications for individual patients under physician prescription, distinct from manufacturers of FDA-approved drugs.
- Research Use Only (RUO)
- A regulatory designation for laboratory chemicals not approved for human or veterinary therapeutic use. Products labeled RUO are intended exclusively for in-vitro and preclinical research applications.
- Therapeutic Use
- Use of a substance for therapeutic application in humans or animals, distinct from research use. Therapeutic use is regulated under FDA drug, biologic, and compounding rules and falls outside the Research Use Only research peptide framework.
- Bulk Drug Substance List
More from the Blog
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
